AVROBIO
One Kendall Square
Building 300, Suite 201
Cambridge
MA
02139
United States
Tel: 617.914.8420
Website: https://avrobio.com/
Email: info@AVROBIO.com
About AVROBIO
AVROBIO, Inc., a leader in lentiviral-based gene therapies, is a clinical-stage company developing disruptive therapies that have the potential to transform patients’ lives with a single dose. The Company is focused on the development of its gene therapy candidate, AVR RD 01, in Fabry disease, as well as additional gene therapy programs in other lysosomal storage disorders including Gaucher disease, cystinosis and Pompe disease. AVROBIO’s lentiviral platform has broad potential for other rare and non-rare genetic diseases.
We are headquartered in Cambridge, MA and have offices in Toronto, ON. Please visit our website www.avrobio.com for more information on who we are, what we care about and how we are bringing these therapies to our patients.
153 articles with AVROBIO
-
AVROBIO Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Update
3/23/2023
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today reported financial results for the fourth quarter and year ended Dec. 31, 2022 and provided a business update.
-
AVROBIO to Participate in Cowen’s 43rd Annual Health Care Conference
3/3/2023
AVROBIO, Inc today announced that members of its senior management team are scheduled to participate in a panel titled “Orphan Neuro Corporate Panel” at Cowen’s 43rd Annual Health Care Conference on Tuesday, March 7, 2023 at 10:30 AM ET.
-
AVROBIO to Present Clinical and Preclinical Data from Lysosomal Disorder Gene Therapy Pipeline at WORLDSymposium™ 2023
2/9/2023
AVROBIO to Present Clinical and Preclinical Data from Lysosomal Disorder Gene Therapy Pipeline at WORLD Symposium ™ 2023.
-
AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - January 5, 2023
1/5/2023
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company working to free people from a lifetime of genetic disease, today announced that the company has granted an aggregate of 7,500 restricted stock units (RSUs) to one new employee as an inducement award under the company’s 2019 Inducement Plan.
-
AVROBIO is planning a Phase II/III registrational trial for its Gaucher Disease Type 3 (GD3) gene therapy candidate, AVR-RD-02, in 2023.
-
AVROBIO Announces New Positive Clinical Data and Outlines Clinical Development Plan Following Regulatory Discussions for its Gaucher Disease Gene Therapy
12/7/2022
AVROBIO, Inc. today announced new interim pharmacokinetic, pharmacodynamic and clinical efficacy data, showing stabilization or reversal of multiple clinically relevant measures in five patients with Gaucher disease after they received a single dose of AVR-RD-02, an investigational hematopoietic stem cell (HSC) gene therapy.
-
Mission Bio's single-cell transduction assay adopted for AVROBIO's gene therapy pipeline
11/29/2022
Mission Bio, the pioneer in high-throughput single-cell DNA and multi-omics analysis, announced the first-time deployment of one single-cell transduction assay across gene therapy company AVROBIO's lysosomal disorder pipeline.
-
AVROBIO to Share Comprehensive Gaucher Disease Program Update
11/17/2022
AVROBIO, Inc. today announced that it will host a virtual Gaucher Disease Program Update for analysts and investors on Wednesday, Dec. 7, 2022, starting at 8 am ET.
-
AVROBIO Reports Third Quarter 2022 Financial Results and Provides Business Update
11/8/2022
AVROBIO, Inc today reported financial results for the third quarter ended Sept. 30, 2022 and provided a business update.
-
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - November 03, 2022
11/3/2022
AVROBIO, Inc. announced that the company has granted an aggregate of 13,000 restricted stock units to two new employees as inducement awards under the company’s 2019 Inducement Plan.
-
AVROBIO Receives Rare Pediatric Disease Designation from the U.S. FDA for First-in-Class Gene Therapy for Gaucher Disease
10/27/2022
AVROBIO, Inc today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to AVR-RD-02, a first-in-class investigational gene therapy.
-
AVROBIO Announces Completion of Patient Dosing in First Gene Therapy Clinical Trial for Cystinosis
10/25/2022
AVROBIO, Inc today announced that the sixth and final patient has been dosed in the collaborator-sponsored, Phase 1/2 clinical trial of an investigational gene therapy for the treatment of cystinosis.
-
AVROBIO Granted ILAP Designation from U.K. MHRA for First-in-Class Gene Therapy for Gaucher Disease
10/18/2022
AVROBIO, Inc today announced that the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) has granted an Innovation Passport under the Innovative Licensing and Access Pathway (ILAP) to investigational AVR-RD-02, a first-in-class gene therapy that uses patients’ own hematopoietic stem cells to treat Gaucher disease, a rare lysosomal disorder that can lead multiorgan pathology, clinical morbidity and early mortality.
-
AVROBIO Reports Favorable Data on Use of Combined State-of-the-art In Vitro Cell-based Assays to Identify Potential Genotoxicity Risk of Integrating Vectors During Preclinical Development
10/11/2022
AVROBIO Reports Favorable Data on Use of Combined State-of-the-art In Vitro Cell-based Assays to Identify Potential Genotoxicity Risk of Integrating Vectors During Preclinical Development.
-
AVROBIO to Present New Preclinical Data on Vector Safety at ESGCT Annual Congress
9/27/2022
AVROBIO, Inc. today announced that it will present new preclinical data on novel assays used to evaluate lentiviral vector safety at the 29th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT), Oct. 11-14, 2022 in Edinburgh, Scotland.
-
The U.S. FDA had a busy week with a range of drug approvals, advisory committee meetings and classification announcements.
-
The FDA granted rare pediatric disease designation to AVR-RD-04, an experimental gene therapy treatment for the lysosomal storage disease cystinosis, AVROBIO announced Tuesday.
-
AVROBIO Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration (FDA) for First Gene Therapy in Development for Cystinosis
9/20/2022
AVROBIO, Inc today announced that the U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation to AVR-RD-04.
-
AVROBIO Announces Neuronopathic Mucopolysaccharidosis Type II (nMPS-II) or Hunter Syndrome Clinical Trial Application (CTA) Accepted by U.K. Regulatory Agency to Initiate Pediatric Phase 1/2 Gene Therapy Trial
9/14/2022
AVROBIO Announces Neuronopathic Mucopolysaccharidosis Type II (nMPS-II) or Hunter Syndrome Clinical Trial Application (CTA) Accepted by U.K. Regulatory Agency to Initiate Pediatric Phase 1/2 Gene Therapy Trial.
-
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - September 08, 2022
9/8/2022
AVROBIO, Inc. announced that the company has granted an aggregate of 58,000 restricted stock units to three new employees as inducement awards under the company’s 2019 Inducement Plan.